Tirzepatide: Difference between revisions
No edit summary |
(Add References section) |
||
| (One intermediate revision by one other user not shown) | |||
| Line 1: | Line 1: | ||
Tirzepatide is a dual GIP and GLP-1 agonist approved for the treatment of type 2 diabetes and also used off-label for obesity treatment | Tirzepatide is a dual GIP and GLP-1 agonist approved for the treatment of type 2 diabetes and also used off-label for obesity treatment | ||
==Side Effects== | |||
*Pancreatitis | |||
*Nausea | |||
*Vomiting | |||
*Abdominal pain | |||
==References== | |||
<references/> | |||
[[Category:Pharmacology]] | [[Category:Pharmacology]] | ||
Latest revision as of 09:15, 22 March 2026
Tirzepatide is a dual GIP and GLP-1 agonist approved for the treatment of type 2 diabetes and also used off-label for obesity treatment
Side Effects
- Pancreatitis
- Nausea
- Vomiting
- Abdominal pain